(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment

(PQ7) 食管肿瘤和微环境的体内细胞光学成像

基本信息

批准号：
9906856
负责人：
Lev T Perelman
金额：
$ 50.41万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-05-16 至 2022-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9906856
关键词：
Address Adopted Area Biological Biometry Biopsy Cancer Biology Cattle Clinical Clinical Data Clinical Research Complement Computer Analysis Computer software Connective Tissue Contrast Media Detection Development Disease Progression Doctor of Philosophy Drug Targeting Dysplasia Endoscopes Endoscopy Epithelial Epithelium Esophageal Neoplasms Esophageal Tissue Esophagus FDA approved Functional Imaging Gastroenterologist Gastroenterology Goals Heterogeneity Histopathology Image Imaging technology Institutional Review Boards International Intervention Israel Laboratories Light Light-Scattering Spectroscopy Malignant Neoplasms Malignant neoplasm of esophagus Measurement Measures Medical center Medicine Microscopy Monitor Morphology Nature Neoadjuvant Therapy Nuclear Oncology Operative Surgical Procedures Optics Organ Pathology Patients Pharmaceutical Preparations Principal Investigator Prior Chemotherapy Reproducibility Research Personnel Resected Resolution Sampling Scanning Site Statistical Data Interpretation Surgical Pathology Survival Rate System Techniques Technology Testing Time Tissues absorption anatomic imaging angiogenesis base bioimaging cancer cell cancer imaging cancer therapy cancer type cell type chemotherapy combinatorial density diffuse reflectance spectroscopy experience experimental study high risk imaging modality imaging system improved in vivo in vivo imaging in vivo optical imaging instrumentation live cell imaging microscopic imaging multidisciplinary neoplastic cell novel novel diagnostics optical imaging outcome forecast personalized medicine photonics programs public health relevance spectrograph spectroscopic imaging standard of care targeted treatment tissue phantom treatment response tumor tumor microenvironment

项目摘要

DESCRIPTION (provided by applicant): In this application we propose to develop the in vivo native contrast endoscopic imaging system that can identify cellular composition of the esophageal cancer tumors and their microenvironment in order to determine the optimal course of cancer therapy. Esophageal cancer is one of the deadliest forms of cancers with an overall 14% five-year survival rate. The survival rate among operable cancers is 22%, which increases to 37% with the use of chemotherapy prior to surgery as a neoadjuvant therapy. Currently, there are several FDA-approved chemotherapy drugs, which can be used in various combinations. Each of these drugs targets particular cancer cell types. Because tumors are almost always composed of several cancer cell types, combinatorial therapies are most effective. The only existing way of determining the cell type of the cancer is histopathology, which samples a small proportion of the tumor and, given the large heterogeneity between different tumor areas, is prone to biopsy errors. Additionally, there is no good way of determining the cancer responsiveness to the chemotherapy, which is closely related to the types of cells composing the tumor and the tumor microenvironment. Thus, the largest impediment for determining optimal targeted therapies for esophageal cancer treatment is the absence of the in vivo imaging method that can identify cancer cell types, tumor microenvironment, and are able to closely monitor treatment progress. Due to its ability to sense cellular organization of tumors and identify cell types, while providing gross anatomical imaging, light scattering spectroscopy (LSS) based imaging would be uniquely equipped to address the problem of identifying the cytotypes and cytotype distributions of cancer tumors. We propose to complement LSS information with diffuse reflectance spectroscopy (DRS) information which is sensitive to the microenvironment of the tumor, such as degree of angiogenesis and connective tissue density. Therefore, the purpose of this program is to extend the LSS and DRS technologies and develop native contrast real time dual mode endoscopic spectral imaging system (DMESIS) and test it in clinical experiments in patients with suspected esophageal cancer by comparing to histopathology results from tumor biopsies.

描述（由申请人提供）：在本申请中，我们建议开发体内天然对比内窥镜成像系统，该系统可以识别食管癌肿瘤的细胞组成及其微环境，以确定食管癌的最佳治疗方案。具有五年总体生存率的最致命癌症类型中，可手术癌症的生存率为 22%，如果在手术前使用化疗作为治疗手段，则生存率可增加至 37%。新辅助治疗。目前，有几种 FDA 批准的化疗药物，每种药物都针对特定的癌细胞类型，因此组合疗法是最有效的。确定癌症细胞类型的唯一现有方法是组织病理学，它对肿瘤的一小部分进行采样，并且考虑到不同肿瘤区域之间的巨大异质性，很容易出现活检错误。此外，没有确定细胞类型的好方法。癌症的反应性化疗与组成肿瘤的细胞类型和肿瘤微环境密切相关，因此，确定食管癌治疗最佳疗法的最大障碍是缺乏能够识别癌细胞类型、肿瘤的靶向体内成像方法。由于其能够感知肿瘤细胞组织并识别细胞类型，同时提供大体解剖成像，基于光散射光谱（LSS）的成像将具有独特的能力来解决识别问题。我们建议用对肿瘤微环境敏感的漫反射光谱（DRS）信息来补充LSS信息，例如血管生成程度和结缔组织密度。是扩展LSS和DRS技术，开发原生对比实时双模式内窥镜光谱成像系统（DMESIS），并通过与疑似食管癌患者的组织病理学结果进行比较，在临床实验中对其进行测试肿瘤生物学。